These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35574376)

  • 1. MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression.
    Perrone C; Pomella S; Cassandri M; Pezzella M; Milano GM; Colletti M; Cossetti C; Pericoli G; Di Giannatale A; de Billy E; Vinci M; Petrini S; Marampon F; Quintarelli C; Taulli R; Roma J; Gallego S; Camero S; Mariottini P; Cervelli M; Maestro R; Miele L; De Angelis B; Locatelli F; Rota R
    Front Oncol; 2022; 12():835642. PubMed ID: 35574376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
    Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
    Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M
    Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
    Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
    Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAK Signaling in Rhabdomyosarcoma.
    Perrone C; Pomella S; Cassandri M; Braghini MR; Pezzella M; Locatelli F; Rota R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
    Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
    Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
    Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
    Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The botanical drug PBI-05204, a supercritical CO
    Vaccaro S; Rossetti A; Porrazzo A; Camero S; Cassandri M; Pomella S; Tomaciello M; Macioce G; Pedini F; Barillari G; Marchese C; Rota R; Cenci G; Tombolini M; Newman RA; Yang P; Codenotti S; Fanzani A; Megiorni F; Festuccia C; Minniti G; Gravina GL; Vulcano F; Milazzo L; Marampon F
    Front Pharmacol; 2022; 13():1071176. PubMed ID: 36532747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling.
    Slemmons KK; Deel MD; Lin YT; Oristian KM; Kuprasertkul N; Genadry KC; Chen PH; Chi JT; Linardic CM
    Biol Open; 2021 Feb; 10(2):. PubMed ID: 33372065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaks.
    Cassandri M; Porrazzo A; Pomella S; Noce B; Zwergel C; Aiello FA; Vulcano F; Milazzo L; Camero S; Pajalunga D; Spada M; Manzi V; Gravina GL; Codenotti S; Piccione M; Tomaciello M; Signore M; Barillari G; Marchese C; Fanzani A; De Angelis B; Quintarelli C; Vakoc CR; Chen EY; Megiorni F; Locatelli F; Valente S; Mai A; Rota R; Marampon F
    Cell Death Discov; 2024 Aug; 10(1):351. PubMed ID: 39107280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
    Wu JT; Cheuk A; Isanogle K; Robinson C; Zhang X; Ceribelli M; Beck E; Shinn P; Klumpp-Thomas C; Wilson KM; McKnight C; Itkin Z; Sotome H; Hirai H; Calleja E; Wacheck V; Gouker B; Peer CJ; Corvalan N; Milewski D; Kim YY; Figg WD; Edmondson EF; Thomas CJ; Difilippantonio S; Wei JS; Khan J
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
    Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R
    Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.